Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Genetic constitution can influence changes in tumor growth: Study

Genetic constitution can influence changes in tumor growth: Study

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Researchers take first step towards understanding of rare skin cancer

Researchers take first step towards understanding of rare skin cancer

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

BioCancell reports results of BC-819 Phase I/IIa clinical trial for pancreatic cancer

Perrigo first quarter revenue increases 21% to record $641 million

Perrigo first quarter revenue increases 21% to record $641 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.